Header

UZH-Logo

Maintenance Infos

NANOG priming before full reprogramming may generate germ cell tumours


Grad, I; Hibaoui, Y; Jaconi, M; Chicha, L; Bergström-Tengzelius, R; Sailani, M R; Pelte, M F; Dahoun, S; Mitsiadis, T A; Töhönen, V; Bouillaguet, S; Antonarakis, S E; Kere, J; Zucchelli, M; Hovatta, O; Feki, A (2011). NANOG priming before full reprogramming may generate germ cell tumours. European Cells and Materials, 22:258-274.

Abstract

Reprogramming somatic cells into a pluripotent state brings patient-tailored, ethical controversy-free cellular therapy closer to reality. However, stem cells and cancer cells share many common characteristics; therefore, it is crucial to be able to discriminate between them. We generated two induced pluripotent stem cell (iPSC) lines, with NANOG pre-transduction followed by OCT3/4, SOX2, and LIN28 overexpression. One of the cell lines, CHiPS W, showed normal pluripotent stem cell characteristics, while the other, CHiPS A, though expressing pluripotency markers, failed to differentiate and gave rise to germ cell-like tumours in vivo. Comparative genomic hybridisation analysis of the generated iPS lines revealed that they were genetically more stable than human embryonic stem cell counterparts. This analysis proved to be predictive for the differentiation potential of analysed cells. Moreover, the CHiPS A line expressed a lower ratio of p53/p21 when compared to CHiPS W. NANOG pre-induction followed by OCT3/4, SOX2, MYC, and KLF4 induction resulted in the same tumour-inducing phenotype. These results underline the importance of a re-examination of the role of NANOG during reprogramming. Moreover, this reprogramming method may provide insights into primordial cell tumour formation and cancer stem cell transformation.

Abstract

Reprogramming somatic cells into a pluripotent state brings patient-tailored, ethical controversy-free cellular therapy closer to reality. However, stem cells and cancer cells share many common characteristics; therefore, it is crucial to be able to discriminate between them. We generated two induced pluripotent stem cell (iPSC) lines, with NANOG pre-transduction followed by OCT3/4, SOX2, and LIN28 overexpression. One of the cell lines, CHiPS W, showed normal pluripotent stem cell characteristics, while the other, CHiPS A, though expressing pluripotency markers, failed to differentiate and gave rise to germ cell-like tumours in vivo. Comparative genomic hybridisation analysis of the generated iPS lines revealed that they were genetically more stable than human embryonic stem cell counterparts. This analysis proved to be predictive for the differentiation potential of analysed cells. Moreover, the CHiPS A line expressed a lower ratio of p53/p21 when compared to CHiPS W. NANOG pre-induction followed by OCT3/4, SOX2, MYC, and KLF4 induction resulted in the same tumour-inducing phenotype. These results underline the importance of a re-examination of the role of NANOG during reprogramming. Moreover, this reprogramming method may provide insights into primordial cell tumour formation and cancer stem cell transformation.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

110 downloads since deposited on 20 Jul 2012
9 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Center for Dental Medicine > Institute of Oral Biology
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Physical Sciences > Bioengineering
Life Sciences > Biochemistry
Physical Sciences > Biomaterials
Physical Sciences > Biomedical Engineering
Life Sciences > Cell Biology
Language:English
Date:2011
Deposited On:20 Jul 2012 09:22
Last Modified:23 Jan 2022 22:04
Publisher:European Cells and Materials
ISSN:1473-2262
Funders:Swiss National Foundation (grant 310000-119938/1), Roche Research Foundation, Ernst & Lucie Schmidheiny Foundation, Geneva University Hospitals, Genico, Swedish Research Council
OA Status:Hybrid
Publisher DOI:https://doi.org/10.22203/eCM.v022a20
Official URL:http://www.ecmjournal.org/journal/papers/vol022/vol022a20.php
PubMed ID:22071697
Project Information:
  • : FunderSNSF
  • : Grant ID
  • : Project TitleSwiss National Foundation (grant 310000-119938/1)
  • : Funder
  • : Grant ID
  • : Project TitleRoche Research Foundation
  • : Funder
  • : Grant ID
  • : Project TitleErnst & Lucie Schmidheiny Foundation
  • : Funder
  • : Grant ID
  • : Project TitleGeneva University Hospitals
  • : Funder
  • : Grant ID
  • : Project TitleGenico
  • : Funder
  • : Grant ID
  • : Project TitleSwedish Research Council
  • Content: Published Version